EIB

European Investment Bank (EIB) provides lending, borrowing, and treasury services primarily in the European Union. The company offers project loans for the public and private sectors; loans to banks and other intermediaries; structured finance products; guarantees and securitization instruments for senior and subordinated debts; project bonds; equity and fund investment products such as infrastructure equity and debt funds, and environmental funds; and venture capital funds and security packages for funds. The company also offers microfinance; risk sharing finance for research, development, and innovation projects; finance and technical expertise for sustainable energy projects; infrastructure project advisory services; support for urban development projects; guarantees for transport infrastructure; and funding for public-private partnerships and small- and medium-sized enterprises. EIB serves the transportation, global loans, energy, industry, health, education, water, sewerage, infrastructure, services, telecommunications, agriculture, and fisheries sectors. European Investment Bank was founded in 1958 and is based in Luxembourg.

Nicola Beer

Vice President

Markus Berndt

Acting Managing Director of EIB Global, Head of Operations

Ambroise Fayolle

Vice President

Werner Hoyer

President

Kyriacos Kakouris

Vice President

Jean-Christophe Laloux

Director General

Emma Navarro

Vice President

Alexander Stubb

Vice President

Past deals in Biofuel

Inbiose

Debt Financing in 2021
Inbiose NV, based in Ghent, Belgium, specializes in the research, development, and production of specialty carbohydrates, particularly Human Milk Oligosaccharides (HMOs). Utilizing its GlycoActives technology platform, the company focuses on cost-effective processes for large-scale production of complex carbohydrates, catering to both human and animal health markets. Inbiose offers a diverse range of products, including infant nutrition solutions, probiotics, and nutraceuticals, aimed at enhancing immune defenses, brain development, and gastrointestinal health. Their product line features various specialty carbohydrates like L-fucose and L-ribose, alongside human milk bioactives for food formulations and dietary supplements. Additionally, Inbiose engages in biological feasibility studies, fermentation protocol development, and process optimization, serving a wide array of industries, including biomedical and agro sectors. The company collaborates with various partners in scientific, life sciences, and industrial fields through licensing, co-development, and manufacturing contracts. Established in 2013, Inbiose is committed to advancing the production of specialty carbohydrates for health applications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.